Phase I, Dose-Escalation, 2-Part Trial of Poly(ADP-Ribose) Polymerase Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2017 |
|---|---|
| Enthalten in: |
Cancer discovery - (2017) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
de Bono, Johann [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| doi: |
10.1158/2159-8290.CD-16-1250 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1993710558 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1993710558 | ||
| 003 | DE-627 | ||
| 005 | 20240403170540.0 | ||
| 007 | tu | ||
| 008 | 170512s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1158/2159-8290.CD-16-1250 |2 doi | |
| 028 | 5 | 2 | |a PQ20170721 |
| 035 | |a (DE-627)OLC1993710558 | ||
| 035 | |a (DE-599)GBVOLC1993710558 | ||
| 035 | |a (PRQ)crossref_primary_10_1158_2159_8290_CD_16_12500 | ||
| 035 | |a (KEY)N0374561220170000000000000000phaseidoseescalation2parttrialofpolyadpribosepolym | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.81 |2 bkl | ||
| 084 | |a 44.81 |2 bkl | ||
| 100 | 1 | |a de Bono, Johann |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Phase I, Dose-Escalation, 2-Part Trial of Poly(ADP-Ribose) Polymerase Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 700 | 1 | |a Ramanathan, Ramesh K |4 oth | |
| 700 | 1 | |a Mina, Lida |4 oth | |
| 700 | 1 | |a Chugh, Rashmi |4 oth | |
| 700 | 1 | |a Glaspy, John |4 oth | |
| 700 | 1 | |a Rafii, Saeed |4 oth | |
| 700 | 1 | |a Kaye, Stan |4 oth | |
| 700 | 1 | |a Sachdev, Jasgit |4 oth | |
| 700 | 1 | |a Heymach, John |4 oth | |
| 700 | 1 | |a Smith, David C |4 oth | |
| 700 | 1 | |a Henshaw, Joshua W |4 oth | |
| 700 | 1 | |a Herriott, Ashleigh |4 oth | |
| 700 | 1 | |a Patterson, Miranda |4 oth | |
| 700 | 1 | |a Curtin, Nicola J |4 oth | |
| 700 | 1 | |a Byers, Lauren Averett |4 oth | |
| 700 | 1 | |a Wainberg, Zev A |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer discovery |d Philadelphia, Pa. : American Association for Cancer Research, 2011 |g (2017) |w (DE-627)667480021 |w (DE-600)2625242-9 |w (DE-576)427254787 |x 2159-8274 |7 nnns |
| 773 | 1 | 8 | |g year:2017 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1158/2159-8290.CD-16-1250 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | b | k | |a 44.81 |q AVZ |
| 936 | b | k | |a 44.81 |j Onkologie |j Onkologie |q VZ |
| 951 | |a AR | ||
| 952 | |j 2017 | ||